Phathom Pharmaceuticals, Inc. Stock Price, News & Analysis

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) has announced that its management team will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 10:00 a.m. ET. The conference runs from June 1-4, 2021, during which management will also engage in one-on-one meetings. Investors can access a live webcast and archived recording via the Phathom website, available for 90 days post-event. Phathom focuses on developing treatments for gastrointestinal diseases, with exclusive rights to vonoprazan for acid-related disorders.

Phathom Pharmaceuticals (NASDAQ: PHAT) reported a positive Phase 3 trial outcome for vonoprazan in treating H. pylori infections, meeting all primary and secondary endpoints. The FDA granted additional qualified infectious disease product (QIDP) designations to vonoprazan-based therapies. The company is set to submit New Drug Applications (NDAs) in Q4 2021. Despite a net loss of $34.8 million in Q1 2021, cash reserves of $238 million are projected to fund operations through Q4 2022.

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) announced its participation in the Bank of America Securities 2021 Virtual Healthcare Conference on May 13, 2021, at 8:45 a.m. ET. Members of the management team will engage in a fireside chat and conduct one-on-one meetings. Interested parties can access the live webcast and a subsequent recording on Phathom's website, available for 90 days post-event. The company focuses on developing treatments for gastrointestinal diseases, including its late-stage candidate, vonoprazan, a novel potassium competitive acid blocker.

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) announced successful results from its pivotal Phase 3 trial, PHALCON-HP, which tested vonoprazan-based treatment regimens for H. pylori eradication. Both vonoprazan triple therapy (84.7% eradication rate) and dual therapy (78.5%) surpassed the standard lansoprazole triple therapy (78.8%). Phathom plans to submit New Drug Applications (NDA) by Q4 2021. The trial highlighted the need for improved therapies facing rising antibiotic resistance. The safety profile of vonoprazan was comparable to existing treatments, with adverse event rates generally low.

Phathom Pharmaceuticals (Nasdaq: PHAT) announced participation in the 20th Annual Needham Virtual Healthcare Conference on April 13, 2021, at 10:15 a.m. ET. The management team will also hold one-on-one meetings during the event from April 12-15, 2021. For access to the live webcast and archived recording, visit the Phathom website. The company focuses on developing treatments for gastrointestinal diseases and has in-licensed vonoprazan, a potassium competitive acid blocker targeting acid-related disorders.

Phathom Pharmaceuticals (Nasdaq: PHAT) reported its financial results for Q4 and FY 2020, revealing a net loss of $53.7 million in Q4, down from $98 million in Q4 2019, and a total net loss of $129.1 million for the year, improved from $255.1 million in 2019. The company completed patient enrollment in pivotal Phase 3 trials for vonoprazan for erosive esophagitis and H. pylori infections. They raised $89 million in a public offering to fund clinical development. 2021 milestones include expected results from these trials and submission of an NDA for H. pylori.

Phathom Pharmaceuticals (Nasdaq: PHAT) has completed patient enrollment in its pivotal Phase 3 clinical trial, PHALCON-HP, evaluating vonoprazan for H. pylori infection. The trial includes over 1,000 patients and aims to provide topline results in Q2 2021. The company also expects to submit a New Drug Application for H. pylori treatment in H2 2021. Vonoprazan, a potassium-competitive acid blocker, has shown promise in eradicating H. pylori and has received FDA Fast Track designation. The trial's success could significantly address rising antibiotic resistance.

Phathom Pharmaceuticals (Nasdaq: PHAT) announced a public offering of 2,250,000 shares at $42.00 per share, aiming for gross proceeds of $94.5 million before expenses. The offering is expected to close around December 21, 2020. Proceeds will fund clinical development of vonoprazan, a treatment for gastrointestinal diseases, and cover general corporate needs. Underwriters have a 30-day option to purchase an additional 337,500 shares. Jefferies, Evercore ISI, Guggenheim Securities, and BMO Capital Markets are managing the offering.

Phathom Pharmaceuticals (Nasdaq: PHAT) announced plans for a public offering of 2,250,000 shares of common stock, with an option for underwriters to purchase an additional 337,500 shares. The offering aims to fund the clinical development of vonoprazan, a treatment for gastrointestinal diseases. The net proceeds will also support working capital and pre-commercial activities. The offering is subject to market conditions, and a detailed prospectus will be filed with the SEC.